High-Resolution Genetics Identifies the Lipid Transfer Protein Sec14p as Target for Antifungal Ergolines. by Filipuzzi, I. et al.
RESEARCH ARTICLE
High-Resolution Genetics Identifies the Lipid
Transfer Protein Sec14p as Target for
Antifungal Ergolines
Ireos Filipuzzi1*, Simona Cotesta1, Francesca Perruccio1, Britta Knapp1, Yue Fu2,
Christian Studer1, Verena Pries1, Ralph Riedl1, Stephen B. Helliwell1, Katarina
T. Petrovic1, N. Rao Movva1, Dominique Sanglard3, Jianshi Tao2, Dominic Hoepfner1
1 Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland, 2 Genomics Institute
of the Novartis Research Foundation, San Diego, California, United States of America, 3 Institute of
Microbiology, University of Lausanne and University Hospital Center, Lausanne, Switzerland
* ireos.filipuzzi@novartis.com
Abstract
Invasive infections by fungal pathogens cause more deaths than malaria worldwide. We
found the ergoline compound NGx04 in an antifungal screen, with selectivity over mam-
malian cells. High-resolution chemogenomics identified the lipid transfer protein Sec14p
as the target of NGx04 and compound-resistant mutations in Sec14p define compound-
target interactions in the substrate binding pocket of the protein. Beyond its essential lipid
transfer function in a variety of pathogenic fungi, Sec14p is also involved in secretion of
virulence determinants essential for the pathogenicity of fungi such as Cryptococcus
neoformans, making Sec14p an attractive antifungal target. Consistent with this dual
function, we demonstrate that NGx04 inhibits the growth of two clinical isolates of C. neo-
formans and that NGx04-related compounds have equal and even higher potency against
C. neoformans. Furthermore NGx04 analogues showed fungicidal activity against a flu-
conazole resistant C. neoformans strain. In summary, we present genetic evidence that
NGx04 inhibits fungal Sec14p and initial data supporting NGx04 as a novel antifungal
starting point.
Author Summary
Emerging resistance to antibiotics led to an inglorious revival of infectious diseases. Fur-
thermore, in the past 30 years, only one novel anti-fungal target has been discovered
which was used to develop therapies against. Therefore pathogen-selective targets and
knowledge about possible resistance determinants are of utmost importance to success-
fully develop newmedicines. Here we describe the identification of anti-fungal ergolines,
targeting the lipid transfer protein Sec14p, and inhibiting the growth of two clinical iso-
lates of the pathogenic fungusCryptococcus neoformans. Both, compound and target rep-
resent attractive points for further investigations: Sec14p as it differs significantly from the
human homolog and as it has been implicated in fungal viability and pathogenicity, and,
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Introduction
Severe invasive fungal infections (IFIs) are life-threatening and associated with high mortality
[1]. Candida albicans (mortality: 20–50%) [2], Cryptococcus neoformans (mortality: 20–70%)
[3] and Aspergillus fumigatus (mortality: 50–90%) [4] represent the major human fungal path-
ogens that have devastating effects on mostly, but not exclusively, immune compromised indi-
viduals such as HIV patients, premature infants, diabetics, chemotherapy patients, organ
transplant recipients and aging people [1, 5]. Currently marketed drugs suffer from limited effi-
cacy and bioavailability, narrow species spectrumand high toxicity [6, 7] and the development
of novel drugs against fungal-selectiveprotein targets is challenging due to the high evolution-
ary conservation between fungi and man. This results in a limited number of druggable nodes
and thus restricted chemical matter [8]. Only one new antifungal drug class to treat systemic
infections has been approved in the US in the last three decades, the β-glucan synthase inhibi-
tors echinocandins (reviewed in [9]). Efficacy of echinocandins however is limited, as they suf-
fer from poor bioavailability [10]. New fungal-selective targets are thus needed to screen for
novel chemotypes to fight these infections [6, 8].
The virulence of C. neoformans is largely dependent on its secretionmachinery, as many of
the molecules required to exert its virulence are extracellular [11, 12]. Secreted factors include
the major polysaccharide building block of the capsule, enzymes involved in the assembly,
maintenance and integrity of the cell wall as well as other proteins [13–17]. So far three Sec
proteins, Sec4p, Sec6p and Sec14p, have been implicated in secretion of factors essential to vir-
ulence of C. neoformans [12]. Among these three Sec proteins, the phosphatidylinositol and
phosphatidylcholine transfer protein Sec14p is most likely druggable [18], whereas Sec4p, a
Rab family member, or Sec6p, an anchoring protein, represent by far more challenging target
classes like GTPases and protein-protein interactions, respectively. Sec14p has been shown to
be essential not only for virulence, but also for growth [11], a dual role which makes this
enzyme an attractive drug target. Here we show the characterization of a fungal Sec14p inhibi-
tor by using a suite of genetic assays to de-convolute the mode of action of the screening hit,
NGx04, prioritized due to an established track record of ergolines in medicine [19–25]. Che-
mogenomic profiling identified hypersensitivity and resistance of deletion strains related to the
action of Sec14p. Saturating mutagenesis of the SEC14 gene identified four key residues that
reduced NGx04 potency. All identified residues localized into the lipid-binding cavity of the
Sec14 protein suggesting that NGx04 is an active-site inhibitor and competition with the
Sec14p lipid substrates supported this hypothesis. Resistance-residue guided in silico docking
of NGx04 into the lipid-binding cavity outlined critical sites for compound-protein interaction
most of which are conserved in the protein sequence of the pathogen C. neoformans but not in
the human homolog. Testing NGx04 against two clinical isolates of C. neoformans confirmed
antifungal action and lack of pronounced cytotoxicity in human cells. Interestingly, the most
potent NGx04 derivative was found to exert fungicidal activity against a strain resistant to flu-
conazole, a commonly used drug against cryptococcosis.
In summary, we present evidence that NGx04 inhibits fungal Sec14p and initial data sup-
portingNGx04 as a novel antifungal starting point.
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Results
Haploinsufficiency profiling (HIP) and homozygous profiling (HOP) of
NGx04
A high-throughput screen of the Novartis compound archive against S. cerevisiae was per-
formed to identify novel antifungal compounds [26, 27]. The ergot-related compound NGx04
(Fig 1A) was among the validated hits scoring an IC50< 20 μM. Due to the long history of
ergolines in medicine [19–25] this scaffold was selected for target identification by chemoge-
nomic profiling [26]. Haploinsufficiency profiling (HIP) and homozygous profiling (HOP) are
gene-dosage-dependentmethods that assess the effect(s) of compounds against potential tar-
gets encoded by the S. cerevisiae genome [28]. HIP indicates pathways directly affected by the
compound, whereas HOP, with both gene copies deleted, indicates synthetic lethality and iden-
tifies compensating pathways to those directly affected by the compound. Testing NGx04 at
sub-lethal doses (8 μM) in two independent biological replicates and correlating the profiles as
previously published [26] identified the heterozygous deletion of SEC14 to result in signifi-
cantly reduced fitness compared to the rest of the genome-wide heterozygous deletion collec-
tion (HIP) (Fig 1B). In contrast, heterozygous deletion of KES1, which encodes a protein that
negatively regulates Sec14p-dependent secretion [29, 30], resulted in increased fitness (Fig 1B).
Hypersensitivity of the heterozygous SEC14 strain was found to be unique when analyzing the
scores of these two strains in our database capturing profiles of> 4000 diverse compounds
(Fig 1D). Chemical-synthetic interactions of NGx04 (HOP) were identifiedwith homozygous
deletions of the genes encoding the regulatory subunit (SRF1) and the catalytic subunit
(SPO14) of Phospholipase D, a previously identified substrate of Sec14p [31, 32], and ITR1 (Fig
1C), the major myo-inositol transporter in S. cerevisiae [33]. Hypersensitivity of SEC14/sec14,
srf1/srf1, spo14/spo14 or itr1/itr1 and hyposensitivity of KES1/kes1 against NGx04 was con-
firmed by titrating NGx04 across the deletion strains and comparing inhibition to the control
stain ho/ho (Fig 1E HIP and Fig 1F HOP). Taken together, this data suggests that NGx04 inter-
feres with cellular viability at the level of the phosphatidylinositol and phosphatidylcholine
transfer protein Sec14p.
Functional variomics screen for NGx04-resistant mutants
To verify our findings from the chemogenomic profiling studies, a saturation mutagenesis
screening approach [34] was used and supported Sec14p as the target of NGx04. A pool con-
taining approximately 105 plasmid-based,mutagenized Sec14p-variants [34] was plated onto
solid growth media supplemented with 150 μMNGx04, a concentration that prevented colony
formation of wild-type cells. Eighty-eight surviving colonies were isolated, plasmid DNA
encoding the Sec14 proteins isolated and sequenced. This approach yieldedmutations in four
distinct amino acids of Sec14p: Y111H (identified 14 times), Y151H/S (identified 27 times),
V154I (identified 15 times) and S173A/P/L (identified 32 times) (Fig 2A). To confirm that the
mutations were the resistance-defining factors, the plasmids containing the SEC14mutants
were retransformed into wild type yeast. A plasmid containing the wild type copy of SEC14
was used as control to exclude resistance due to SEC14 gene copy-number effects. Spotting for
single colony formation on lethal doses of NGx04 (Fig 2B) as well as growth inhibition titra-
tions (Fig 2C) revealed that each of the four identifiedmutations was sufficient to confer resis-
tance to NGx04. As the cells contained also the endogenous wild type SEC14 allele this data
revealed that the drug resistance was dominant and provided further support that Sec14p is the
growth inhibitory target of NGx04.
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Fig 1. Chemogenomic profiling. Structure, haploinsufficiency profiling (HIP) and homozygous profiling (HOP) of NGx04. A) The structure of
NGx04 is shown. B) HIP and C) HOP were performed around IC30 (8 μM) in duplicates and the average of the profiles is shown. The MADL score is
given on the y-axis and indicates how sensitive a particular deletion strain is to a given compound, compared to its no-drug control. The Z-score is
given on the x-axis and is a statistical measure of how frequently a particular deletion strain is affected within the so far profiled compounds [26].
Circles depict non-essential deletions, whereas squares essential deletions. Hyper-sensitive deletions are found bottom left and hyper-resistant
deletions top right of the panels. D) Hypersensitivity of a heterozygous SEC14/sec14 strain across 4011 diverse compounds (x-axis) is displayed as
Z-score (y-axis). NGx04 (arrow) was found to exert the strongest effect. Validation of the hit candidates from HIP E), HOP F) was performed by single
strain growth inhibition. The indicated strains were grown for 24 h in the presence of increasing concentrations of NGx04 and growth measured by
turbidity (OD600). Duplicate values were determined and used for logistic regression. The calculated IC50 values are displayed.
doi:10.1371/journal.pgen.1006374.g001
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Fig 2. Resistance mapping. Functional variomics screen for NGx04-resistant mutants. A) The SEC14 ORFs
of 88 NGx04-resistant colonies were amplified by PCR and sequenced. Four mutations mapping to the lipid-
binding part of Sec14p were found. The identified amino acid changes with their respective frequencies are given.
B) The plasmids coding for various SEC14 proteins were re-transformed into a fresh wild type yeast strain and
serial dilutions of the cultures spotted on either 150 μM of NGx04 or DMSO control, incubated for 3 days at 30˚C
and scored for growth. C) The strains were grown for 24 h in the presence of increasing concentrations of NGx04
and growth measured by turbidity (OD600). Duplicate values were determined and the 18 h time point was used for
logistic regression. The calculated IC50 values displayed.
doi:10.1371/journal.pgen.1006374.g002
Antifungal Ergolines Target Sec14p
PLOS Genetics | DOI:10.1371/journal.pgen.1006374 November 17, 2016 5 / 19
Phosphatidylinositol (PI) and phosphatidylcholine (PC) competition
Crystal structures of Sec14p and Sec14p-like proteins from various species including S. cerevisi-
sae (PDB ID: 1AUA) and human (PDB ID: 1OLM) have been solved. Although the lipid-bind-
ing pocket of the enzyme is well characterized [35–37] Sec14p has not been crystalizedwhen
bound to phosphatidylethanolamine (PtdEtn) substrate. The crystal structure of the S. cerevisi-
sae Sfh1protein (PDB ID: 3B7Q), sharing 62.3% identity with Sec14p, shows that phosphatidyl-
coline (PC) hydrophobic tail forms van derWaals interactions with a cluster of hydrophobic
residues, whereas the phosphate moiety is interacting with the side-chain hydroxyl groups of
residues S175 and T177, and the nitrogen contacts the phenolic oxygen of Y113 (Fig 3A). Since
the NGx04 resistance-conferring residues were located in the equivalent catalytic site of Sec14p
(Fig 3A) (i.e. S173, corresponding to S175, and T175 to T177 in Sfh1, two residues involved in
H-bonds with PC) we reasoned that NGx04 would bind in the lipid-binding pocket of the
protein.
To test this hypothesis, the S. cerevisisae x-ray structure of Sec14p was used to dock the
NGx04 ligand into the lipid-binding cavity (Fig 3B). In the resulting dockingmodel, the ester
moiety of the ligand formed an H-bond with Y111 while the ergoline amine formed an H-
bond with T175. The ergoline moiety also made van derWaals interactions with the residues
Y122, Y151, S173, M177 and F212. The calculated dockingmodel was in agreement with the
experimental data from the mutagenesis study, as three of the four identified resistance confer-
ring mutations were directly involved in ligand interactions (Y111, Y151 and S173) and the
identifiedV154 residue, although not directly involved in ligand interactions, was only 4.5 Å
away fromNGx04. The model outlines that a larger residue at this position like Isoleucine
would be deleterious for ligand binding. As our docking experiment was biased towards the
lipid-binding cavity we aimed at further supporting evidence for NGx04 binding in this protein
pocket. To do so we tested if NGx04 would compete for phospholipid-binding in the Sec14p
cavity. Wild type S. cerevisiae cells were grown in presence of increasing doses of NGx04 in
medium containing an excess of either phosphatidylinositol (PI) or phosphatidylcholine
(PC) (200 μM). Both lipids, PI and PC, were found to alleviate NGx04-mediated growth
inhibition, supporting a competitive mode of inhibition at the lipid-binding cavity of Sec14
(Fig 3C).
Mammalian cell proliferation and cytotoxicity of NGx04
One key requirement of antifungal medicines is selective inhibition of the pathogen over the
mammalian host. To explore potential undesired activity of NGx04 against mammalian cells
we used the Cancer Cell Line EncyclopediaCCLE, a collection of 512 human cancer cell lines
(broadinstitute.org/ccle). Dose-response curves for NGx04 were generated in a proliferation
assay and IC50 values determined. Although a large number of anti-proliferative compounds
were published to be active across the CCLE collection [38, 39] only one fourth of the cell lines
was found to be sensitive to NGx04 as defined by Amax<50% and IC50<30 μM. Furthermore
the large majority of cells (76%) were not notably affected by NGx04 (Fig 4A). Since HepG2
cells are known to be a suitable tool to profile toxicity of compounds [40], we used this liver-
derived line to assess cytotoxicity of NGx04. A dose-response curvewas generated and an IC50
value of 157.6 μM determined by logistic regression (Fig 4B), again indicating potential selec-
tivity of NGx04 for the fungal protein. Superimposition of the S. cerevisisae Sec14p crystal
structure (PDB ID: 1AUA, blue) and the crystal structure of the human orthologue SEC14L2
(PDB ID: 1OLM, green) (Fig 4C) revealed that although having a similar overall structure fold,
the active site of the two enzymes differ considerably. 16 of 21 amino acid residues within a 5 Å
radius from any atom of the dockedNgx04 ligand were not conserved between the two
Antifungal Ergolines Target Sec14p
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proteins. Critical differences in the active site of the human protein are the residues F178,
C128, I151 and L186 (corresponding to S201, Y151, T175 and M209 in yeast) which form a
smaller and more hydrophobic pocket compared to the yeast protein (Fig 4C). Visualizing the
Fig 3. Active site antagonism. Phosphatidylinositol (PI) and phosphatidylcholine (PC) competition.
A) The crystal structure of Phosphatidylcholine (PC) bound to the yeast Sfh1protein (PDB ID: 3B7Q), (where
R is oleoyl and R’ is palmitol). PC hydrophobic tail forms van der Waals interactions with a cluster of
hydrophobic residue, whereas the phosphate moiety is interacting with the side-chain hydroxyl groups of
residues S175 and T177, and the ethanolamine nitrogen contacts the phenolic oxygen of Y113. B) The
proposed docking pose of NGx04 in the putative binding site of the yeast protein structure is shown (PDB
ID:1AUA). In the suggested binding mode, the ester moiety of the ligand forms a hydrogen bond with Y111
while the ergoline amine forms H-bonds with the T175. The ergoline moiety is also forming van der Waals
interactions with the following residues: Y122, Y151, S173, M177 and F212. C) Wild type yeast was grown in
presence of increasing concentrations of NGx04, supplemented with either 200 μM PI, 200 μM PC or no
phospholipid, incubated at 30˚C and growth followed over time by measuring turbidity (OD600). Duplicate
values were determined and the time points at 18 h were used for logistic regression.
doi:10.1371/journal.pgen.1006374.g003
Fig 4. Fungal selectivity. Mammalian cell growth inhibition and cytotoxicity of NGx04. A) Dose-response curves
for NGx04 were generated in growth inhibition assay and IC50 values determined in duplicates [39]. IC50 values and
growth inhibition (Amax) are displayed. 76% of the tested cell lines were not significantly inhibited by NGx04. B) A dose-
response curves for NGx04 was generated in a MTS cytotoxicity assay using HepG2 cells in triplicates and a toxicity
curve generated by logistic regression. C) Overlay of the crystal structure of the yeast Sec14p (PDB ID: 1AUA, protein
structure highlighted in blue) and its human orthologue SEC14L2 (PDB ID: 1OLM, protein structure highlighted in green)
reveals that the amino acid residues belonging to the putative binding site are not conserved between the yeast and the
human protein. D) Overlay of the docked NGx04 in the yeast Sec14p (PDB ID: 1AUA) and its human orthologue
SEC14L2 (PDB ID: 1OLM). The amino acid residues of the yeast protein structure have been hidden whereas the
surface of the putative binding site of the human protein structure has been added to highlight the difference in the
overall shape between the active site of the two species.
doi:10.1371/journal.pgen.1006374.g004
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solvent accessible surface of the human Sec14pwith NGx04 as a potential ligand revealed that
NGx04 is too big to occupy this smaller binding pocket (see clear ligand bumps towards the
solvent accessible surface) (Fig 4D). In addition, all four NGx04-interacting amino acids identi-
fied by functional variomics are missing in the human enzyme (S1 Fig). In summary, it is plau-
sible that the observed lack of potent activity of NGx04 against human cell lines can be
explained by differences in the catalytic pocket and the absence of proposed NGx04 interacting
residues in the human protein.
C. neoformans growth inhibition by NGx04 scaffolds
Sec14p is reported to be essential for virulence as well as for growth in C. neoformans [11, 12].
The S. cerevisiae and C. neoformans proteins show 53% similarity by pair-wise alignment with
higher conservation of the residues in the lipid-binding pocket (S2 Fig). Furthermore, three of
the four sites identified to be critical for NGx04 sensitivity, are conserved (S2 Fig). In combina-
tion with the current high unmet medical need related to Cryptococcus infections we prioritized
testing of NGx04 and 18 related ergoline scaffold analogs against this pathogen. Two clinical
isolates of C. neoformans (ATCC 36556 and ATCC 90113) were plated in triplicates on increas-
ing drug concentrations and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth)
concentrations were scored after 72 hrs. (Fig 5). NGx04 and analogues including NGx03,
NGx16, NGx07, NGx09 and NGx19 were found to inhibit C. neoformans growth in the tested
dose range. NGx03 appeared to be the most potent compound against ATCC 36556 with a
MIC-2 of 3.13 μg/ml and a MIC-0 of 6.25 μg/ml whereas NGx19 showed a broader spectrum
with a MIC-2 of 12.5μg/ml against the first isolate and a MIC-2 of 6.25μg/ml against the second
strain.
Fluconazole (FLU) is commonly used to treat cryptococcosis [41]. Repeated exposure or
prolonged treatment with azoles, however, can lead to resistance [42–44]. We thus tested the
ability of the most potent compounds to inhibit growth of the FLU-resistant C. neoformans
strain BPY22 [45] and found activity for NGx03 (MIC-2 of 16 μg/ml and MIC-0 of 32 μg/ml)
and weaker activity for NGx16 and NGx19 (S3 Fig), indicating the potential of ergolines to
fight FLU-resistant C. neoformans. We next assessed the mechanism of inhibition, since fungi-
cidal agents, compared to fungistatic agents [46], are associated with decreasedmortality and
found NGx03 and NGx16 to exhibit a fungicidal effect on FLU-sensitive and FLU-resistant C.
neoformans strains (S6 Fig). NGx03 was among the most active compound when tested in sus-
ceptibility assays and thus corroborates with its fungicidal effect in the tested strains.
Analysis of the structure-activity relationship (SAR) of the tested ergolines (Fig 5) revealed
that analogues where the aromatic amino group was substituted by a 2,2,2-trichloroethyl-car-
boxylate moiety scored anti-fungal activity (NGx03 and NGx07), while the analogues with an
unsubstituted, acetylated or formulated aromatic amino group lacked notable activity. Nitro
substitution of the aromatic ring appeared to be tolerated in all positions as the analogue with-
out any substituent was found to be equipotent. In summary, antifungal activity against C. neo-
formans as predicted by the analysis of identifiedNGx04 interacting residues could
experimentally be confirmed.Our limited SAR experiment identified that building off the aro-
matic ring was tolerated enabling future medicinal chemistry approaches with the aim to assess
and optimize potency, spectrumand other pharmacokinetic parameters of this scaffold.
Discussion
Severe IFIs are often life-threatening conditions. The clinical anti-fungal arsenal however is
very limited and the β-glucan synthase inhibitor echinocandin is the only drug developed over
the last three decades that modulates a novel target. In addition, the emergence of resistance
Antifungal Ergolines Target Sec14p
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against established treatments dramatically emphasizes the importance of identifying novel
and selective drug targets. C. neoformans is the most common cause of fungal meningitis
(reviewed in [47], and the invasion of the central nervous system by C. neoformans is strictly
dependent on the secretion of proteins like phospholipase B1 (Plb1) [11], the metalloprotease
Mpr1 [48], building blocks of the capsule, and enzymes involved in the assembly, maintenance
and integrity of the cell wall as well as other proteins [12] [49]. Protein traffic and secretion in
C. neoformans has been described to occur via more than one pathway involving either Sec4p,
Sec6p or Sec14p [12], where the secretion of the key cryptococcalvirulence factor Plb1 is
strictly Sec14p-dependent [11]. Of the three Sec proteins involved, the phosphatidylinositol
and phosphatidylcholine transfer protein Sec14p represents the most promising target, with
the first inhibitory scaffold published recently [18]. Sec4p, a Rab family GTPase, is very difficult
to target, and several pharmaceutical laboratories failed in the past to identify selectivemole-
cules against this target family. Sec6p, an essential subunit of the exocyst complex is a structural
protein which could be modulated by interfering with its interactions to binding partners, how-
ever, tackling protein-protein interactions is difficult and often yields only very limited success.
Genomic fitness analysis has proven to be a powerful approach for mode of action elucida-
tion of test compounds [26, 28, 50–52]. Whereas haploinsufficiency profiling (HIP) can
directly identify the target of a test compound, homozygous profiling (HOP) identifies syn-
thetic lethal and compensatory interactions. Follow up work of a large high-throughput screen-
ing campaign by HIP HOP identifiedNGx04 as a potential Sec14p inhibitor. No chemical
probe, interfering with either Sec4p or Sec6pwas found among the ca 4,000 acquired com-
pound profiles. The heterozygous SEC14 deletion showed dramatically reduced fitness at sub-
lethal NGx04 doses (HIP), indicating that reducing Sec14p expression represents the main
action of NGx04. Interestingly, the heterozygous deletion of Kes1p, a protein which negatively
regulates Sec14p-dependent secretion [29, 30], led to increased fitness as deletion of a repressor
appeared to activate the pathway. The homozygous deletions of the regulatory subunit (Srf1p)
and the catalytic subunit (Spo14p) of PLD were found to be synthetic lethal with inhibiting
Sec14p by NGx04. PLD was described to bypass Sec14mutations [53] by generating a phos-
phatidic acid pool that is utilized in supporting yeast Golgi secretory function. In addition,
deletion of Itr1p, a Myo-inositol sugar transporter, was also found to be synthetic lethal with
Sec14p inhibition, probably by depletion of inositol levels in the cell. Thus, our data indicate
that NGx04 interferes with Sec14p directly or might modulate a Sec14p-dependent process.
Target identification and validation by resistance cloning has often been successful since
mutations in the drug binding pocket of the target can lead to lack of drug binding and thus
resistance. Spontaneous or chemically induced, randommutations were historically screened
for resistance followed by cloning of the responsible single nucleotide polymorphism (SNP)
[54]. An elegant variation of the approach has been published and termed functional variomics
[34]. The functional variomics tool consists of a (nearly) genome-wide collection of plasmid-
based SNPs. Over 90% of the yeast ORFs are represented as pools of 10,000 to 100,000 different
SNPs. Plating the functional variomics pool of SEC14 at inhibitory concentrations of NGx04,
led to the identification of four distinct SNPs, isolated multiple times. Plating the genome-wide
functional variomics pool, led to the identification of only SEC14-relatedmutations (S4 Fig),
supporting that Sec14p is the efficacy target of NGx04. All isolated SEC14 SNPs, Y111H,
Y151H/S, V154I and S173A/P/L, located to the lipid-binding pocket of Sec14p, indicating that
Fig 5. Antifungal testing. C. neoformans growth inhibition by NGx04 scaffolds. NGx04 and close analogues were tested against C.
neoformans ATCC 36556 and ATCC 90113 in a 72 h proliferation assay and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth)
determined. Triplicate values are given in μg/ml. Amphotericin B was included as positive control.
doi:10.1371/journal.pgen.1006374.g005
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NGx04 was a substrate-competitive Sec14p inhibitor. Crystal structures of Sec14 proteins from
various species, including S. cerevisiae [55], have been solved and the lipid-binding pocket of
the enzyme is well characterized [35–37]. The residues S173 and T175 are involved in the coor-
dination of the phosphate moiety whereas the phenolic oxygen of Y111 binds the nitrogen the
substrate PtdEtn. As Y111H and S173A give resistance to NGx04, we postulated that the com-
pound competes for substrate binding which we showed by PI- and PC-mediated suppression
of NGx04-induced growth inhibition. The observeddominant resistance by single mutations is
a concern when consideringNGx04as an anti-fungal lead compound. However, advanced
knowledge on privileged sites than can confer resistance is valuable information and we believe
that a medicinal chemistry program paralleled by the functional variomics approach will allow
the further optimization of NGx04-derived compounds with favorable resistance profiles.
As a precursor for in vivo toxicology studies we assessed the potential of NGx04 to inhibit
proliferation of human cells by determining IC50 values across the Cancer Cell Line Encyclope-
dia. Most of the tested lines were not found to be significantly sensitive and, in addition, a
HepG2-based cytotoxicity assay confirmed this finding. Genetic complementation of an S.cere-
visiae SEC14 homozygous deletion by human SEC14 failed in our hands (S5 Fig), probably due
to evolutionary divergence. Although the lipid transfer function of Sec14 proteins has been
conservedduring evolution, structural differences are found between the S. cerevisiae and
human proteins [56]. The two proteins show a similar overall protein fold, however, specific
differences are found in the lipid-binding pocket where amino acids critical for NGx04 binding
are not conserved between the human and the fungal proteins [57]. These differences affect the
overall shape of the putative binding site, forming a smaller binding pocket in the human active
site. A C. neoformans Sec14p structure is needed to further exploit species-specific features and
guidemedicinal chemistry. Aligning S.cerevisiae SEC14 to C. neoformans SEC14-1 and SEC14-
2 shows that most residues involved in NGx04 binding as well as responsible for mutation-
based resistance are conserved (Y111, Y122, Y151, S173 and T175) (S2 Fig), suggest that
NGx04 binds to the two fungal proteins in a very similar way.
In vitro activity against two clinical isolates of C. neoformans was assessed. NGx04 scored
anti-cryptococcal activity and more potent derivatives were identified. Substitutions of the aro-
matic amino group of the scaffold were found to be critical for its anti-fungal activity, whereas
other residues had less effect. Two features seem to determine potency of the compound class,
the chlorinated carbamate and the aromatic amide (NGx03 and NGx07). NGx03 having both,
an aromatic amide and additionally a trifluoromethyl substituted phenyl, displays the highest
activity. The data density obtained by the limited SAR by inventory did not allow the building
of a high-resolution pharmacophore template. However, tolerated substitutions of the aromatic
ring system demonstrated that NGx04 is amenable to derivatization and comprises an attrac-
tive starting point for a medicinal chemistry program. In addition, NGx03 was also found to
inhibit growth of a FLU-resistant C. neoformans strain (S3 Fig) and furthermore the effect was
found to be cidal S6 Fig), underlining the potential of ergolines to fight C. neoformans
infections.
Some of the compounds presented here were also tested against C. albicans (ATCC 24433),
A. fumigatus (ATCC MYA-3627), R. oryzae (ATCC MYA-4621) and F. solani (ATCC MYA-
3636), but found to be inactive (S8 Fig). Since the fungal Sec14 proteins are evolutionary con-
served, targeting Sec14p seems only to be efficacious in C. neoformans. Sec14p-dependent viru-
lence has only been described for C. neoformans [11] but not for other fungal pathogen. It
remains to be seen if in the future intervening at different nodes of the cellular lipid transfer
pathway might yield novel anti-fungal targets.
From a chemical perspective one might suspect some NGx side groups to be potentially
reactive.We thus tested the cryptococcal active compounds in a rat liver microsome-based
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assay for metabolic stability but could not detect significant degradation (S7 Fig). In addition,
potent activity in rich medium (containing crude cell extracts) and the absence of any cell-
wall/plasmamembrane-stress indicative hits in HIP and HOP [26, 58], support the notion that
this scaffold is stable and selectively targeting Sec14p.
Invasion of the central nervous system by C. neoformans is a prerequisite for fungal menin-
gitis.We thus performed artificialmembrane permeability assays in order to assess the poten-
tial of the cryptococcal active compounds to penetrate the blood brain barrier (S7 Fig). All
tested compounds, with the exception of NGx13, showed high permeability indicating a poten-
tial exposure of the CNS. High permeability of ergolines is expected, as members of the ergoline
class are used as psychedelic narcotics since their discovery.
Although hallucinogenic and toxic effects of ergot alkaloids are known since 600 BC [59], a
first representative was isolated only in 1875 [60]. Today, over 80 ergot alkaloids from fungi
and plants have been described [61] and a number non-hallucinogenic ergolines, or their deriv-
atives, are used in the clinic to treat Parkinson’s disease, acromegaly, hyperprolactinemia, rest-
less-legs syndrome, hypotony, migraine and other diseases (summarized by [61]).
Interestingly, the effects of this substance class are exclusively transmitted via α-adreno-, sero-
tonin- or dopamine receptors in mammals [62]. Identification of NGx04 as Sec14p inhibitor
not only provides the first report of ergolines as non-GPCRmodulators, but also the first activ-
ity of ergolines on lower eukaryotes.
Materials and Methods
Compound handling
Compounds were stored as powders until use. Prior to testing compounds were dissolved as 10
mM stocks into 90% DMSO and kept at 4°C for a maximum of 6 months. Purity and integrity
was analyzed by LC-MS/MS and UV. Solutions only passed QC if correspondingmass could
be identified and the main component concentration was above 85%.
S. cerevisiae strains
The heterozygous and homozygous deletion strain collections were acquired (OpenBiosystems
YSC1055 and YSC1056) and pools generated as describedpreviously [63]. The functional var-
iomics collectionwas obtained from Dr. X. Pan (Baylor College of Medicine, Houston, TX
77030, USA).
C. neoformans strains
C. neoformans strains ATCC 36556, a lung isolate, and ATCC 90113, a cerebrospinal fluid iso-
late, were purchased from ATCC, Manassas, VA (USA). BPY22 was obtained from [45].
Haploinsufficiency profiling (HIP) and homozygous profiling (HOP)
Genomic profiling and microarray analysis were performed as describedpreviously [26].
Functional variomics screen
The functional variomics screen was performed as describedpreviously [34] with the difference
that plasmids of resistant clones were analyzed by Sanger sequencing and not chip hybridiza-
tion: Clones were picked and grown over night in 1 ml of YPD at 30°C in a 96 deep well block.
Cells were then subsequently washed with distilledwater and subjected to a zymolyase treat-
ment prior to purification of plasmid DNA by Wizard SV DNA purification system (Promega)
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Phosphatidylinositol (PI) and phosphatidylcholine (PC) competition
S. cerevisiae BY4741 (Open Biosystems) was grown in YPDmedium in the absence or presence
of additional phosphatidylinositol or phosphatidylcholine (200 μM each, Sigma-Aldrich 79401
or P3556, respectively). OD600 values of exponentially growing yeast cultures were recorded
with a robotic system. Twelve-point serial dilutions were assayed in 96-well plates with a reac-
tion volume of 150 μl.
Crystal structure docking
The S. cerevisiae protein structure (PDB ID 1AUA) has been prepared using the default settings
of the ProteinPreparation Wizard within the Maestro Schrödinger Suite (www.schrodinger.
com). Ligand coordinates have been generated with Corina [64]. This conformation has been
used as a starting point for the docking. The docking procedure was carried out using Glide SP
within the Maestro Schrödinger Suite. After docking the complex protein-ligand has beenmin-
imized usingMacroModel within the Maestro Schrödinger Suite, allowing the ligand to be flex-
ible and keeping the protein rigid.
Mammalian cell growth inhibition
Profiling across the Cancer Cell Line Encyclopediawas performed as describedpreviously [65].
MTS toxicity was determined using a CellTiter 96 AQueous One Solution Cell Proliferation
Assay kit from Peomega.
C. neoformans growth inhibition
Antifungal susceptibility testing was conducted according to the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines for broth microdilution assay M27-A3. Testing was per-
formed in RPMI-1640 (HyClone) with 2.05 mM glutamine, phenol red, without bicarbonate
and buffered with 0.165 mol/l 3-(N-morpholino) propanesulfonic acid (MOPS). The medium
was adjusted to pH 7.0 and sterilizedwith a 0.2 μm filter. Two endpoints were recorded:MIC-0
(complete inhibition with no visible fungal growth) and MIC-2 (prominent inhibition corre-
sponding to>50% growth reduction).
Fungicidal vs fungistatic drug testing
To test the fungistatic or fungicidal effect of the ergolines, the format of the CLSI susceptibility
assay was followed. Briefly, C. neoformans strains were grown overnight in YEPDmedium at
30°C under constant agitation. Cells were then diluted to about 103 cells/ml in RPMI medium
as starting inoculumand 200 μl of this inoculumwas pipetted in 96- well flat bottommicrotiter
plate. The starting inoculumwas subjected to CFU counts in YEPD agar by plating serial
dilutions and 48 hrs. incubation. Drugs were diluted to a final concentration of 16μg/ml and
MIC-0 values determined by the CLSI protocol. After an incubation of 24 hrs. at 35°C, cells
were diluted in RPMI and plated onto YEPD agar for CFU counting. A fungicidal effect was
defined as decreasedCFUs in drug-exposedcultures as compared to CFUs in the starting
inoculum.
Rat liver microsome and artificial membrane permeability assay
Metabolic stability was determined as describedpreviously [66] on a fully automated platform,
the artificialmembrane permeability assays was performed as describedpreviously [67]
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Supporting Information
S1 Fig. Protein comparison 1. Alignment of CnSec14-1p, ScSec14p and HsSec14-2p. The
CLUSTAL 2.1 alignment of C. neoformans, S. cerevisiae andH. sapiens Sec14 proteins is shown
and the NGx04 resistance conferring amino acids highlighted in red.
(EPS)
S2 Fig. Protein comparison 2. Alignment of ScSec14p, CnSec14-1pand CnSec14-2p.The
CLUSTAL 2.1 alignment of S. cerevisiae Sec14p and C. neoformans CnSec14-1p and CnSec14-
2p is shown. Red boxes represent conserved amino acids involved in NGx04 binding in the
three proteins, blue boxes represent non-conserved amino acids.
(EPS)
S3 Fig. Anti-fungal resistance testing. Inhibition of fluconazole resistantC. neoformans.
NGx04 and close analogues were tested against the FLU-resistant C. neoformans BPY22 [45] in
a 48 h proliferation assay and MIC-2 (50% inhibition) and MIC-0 (no visible fungal growth)
determined. Values are given in μM as mean of tree replicates. Fluconazole was included as
control to show hyper-resistance of BPY22.
(EPS)
S4 Fig. Resistancemapping. Functional variomics screen for NGx04-resistantmutants. Sta-
tistics of the primary screen (genome-wide pool) and the secondary screen (SEC14 pool) are
displayed. 1.5 OD600 of the corresponding pools were plated on a 15 cm SD agar dish contain-
ing 150 μMNGx04, resistant clones isolated and analyzed by sequencing of the expressed ORF.
Numbers in parenthesis display the frequency of the isolated ORFs.
(EPS)
S5 Fig. Evolutionary divergence. Complementation of yeast SEC14. A heterozygous SEC14/
sec14 S. cerevisiae strain was transformed with the human SEC14 homologue
(XP_011510441.1) under the control of the ADH1 promotor. Transformants were isolated,
subjected to sporulation, tetrads dissected and analysed for viability. 18 tetrads are shown (hor-
izontal). Only two viable spores per tetrad were found, indicating no genetic complementation.
(EPS)
S6 Fig. Effectivenessof growth inhibition. Fungicidal vs fungistatic effects of ergolines.
Ergolines were tested at 16 μg/ml final concentration for 24 hrs. against FLU-sensitive
(DSY4982) and FLU-resistant (BPY22 and BPY17) C. neoformans isolates [45] for fungicidal
activity and Colony Forming Units in presence (NGxXX) and in absence (inoculum) of com-
pound are displayed as mean of three replicates. Detection limit of the assay was 102 cells/ml.
This value was attributed to samples in which this detection limit was reached.
(EPS)
S7 Fig. Physicochemicalproperties of ergolines. Rat liver microsome and artificialmem-
brane permeability assay. NGx04 and close analogues were tested for metabolic stability (CYP
MetCL) and artificialmembrane permeability (logPAMPA) in duplicates. Value pairs are color
coded and binning is indicated.
(EPS)
S8 Fig. Anti-fungal testing. Fungal pathogen assay. NGx04 and close analogues were tested
against C. albicans (ATCC 24433), A. fumigatus (ATCC MYA-3627), R. oryzae (ATCC MYA-
4621) and F. solani (ATCC MYA-3636) in a 72 h proliferation assay and MIC-2 (50% inhibi-
tion) and MIC-0 (no visible fungal growth) determined. Values are given in μM as mean of
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tree replicates. Amphotericin B was included as positive control.
(EPS)
Acknowledgments
We would like to acknowledge the Novartis HIP HOP team, T. Aust, J. Eichenberger, N. Hart-
mann, C.Wache-Mainier and S. Schuierer for profiling and analyzing the compounds used in
this study. And we would like to thank F. Ischer for performing fungal inhibition assays.
Author Contributions
Conceptualization: IF SC VP DH.
Data curation:KTP.
Formal analysis: IF.




Validation: IF CS RR.
Visualization: IF DH.
Writing – original draft: IF DH.
Writing – review& editing: IF DS.
References
1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden Killers: Human Fungal
Infections. Science Translational Medicine. 2012; 4(165):165rv13. doi: 10.1126/scitranslmed.3004404
PMID: 23253612
2. Arendrup MC SS, Holm A, Nielsen L, Nielsen SD, Knudsen JD, Drenck NE, Christensen JJ, Johansen
HK. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. Journal of
Clinical Microbiology 2011; 49(9):9.
3. Tripathi L, Meena K. Genomic identification of potential targets unique to Candida albicans for the dis-
covery of antifungal agents. Curr Drug Targets. 2014; 15(1):136–49. PMID: 24102473
4. Balloy V, Chignard M. The innate immune response to Aspergillus fumigatus. Microbes and Infection.
2009; 11(12):919–27. doi: 10.1016/j.micinf.2009.07.002 PMID: 19615460
5. Hope W, Natarajan P, Goodwin L. Invasive fungal infections. Clinical Medicine. 2013; 13(5):507–10.
doi: 10.7861/clinmedicine.13-5-507 PMID: 24115712
6. Odds FC. Antifungal agents: their diversity and increasing sophistication. Mycologist. 2003; 17
(02):51–5.
7. Sheng Z. New Lead Structures in Antifungal Drug Discovery. Curr Med Chem 2011; 18(5):768.
8. Denning DWH, William W. Therapy for fungal diseases: opportunities and priorities. Trends in Microbi-
ology. 2010; 18(5):195–204. doi: 10.1016/j.tim.2010.02.004 PMID: 20207544
9. Manzoni B, Franco R., Stronati W., Cohen-Wolkowiez JA. Echinocandins for the nursery: an update.
Curr Drug Metab. 2013; 14(2):203–7. PMID: 22935065
10. Lepak A, Marchillo K., Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase
inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents
Chemother. 2015; 59(2):1265–72. doi: 10.1128/AAC.04445-14 PMID: 25512406
Antifungal Ergolines Target Sec14p
PLOS Genetics | DOI:10.1371/journal.pgen.1006374 November 17, 2016 16 / 19
11. Chayakulkeeree M, Johnston SA, Oei JB, Lev S, Williamson PR, Wilson CF, et al. SEC14 is a specific
requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans. Molec-
ular Microbiology. 2011; 80(4):1088–101. doi: 10.1111/j.1365-2958.2011.07632.x PMID: 21453402
12. Rodrigues M, Djordjevic JT. Unravelling secretion in Cryptococcus neoformans: more than one way to
skin a cat. Mycopathologia. 2012; 173(5–6):407–18. doi: 10.1007/s11046-011-9468-9 PMID:
21898146
13. Cox GM, McDade HC, Chen SCA, Tucker SC, Gottfredsson M, Wright LC, et al. Extracellular phos-
pholipase activity is a virulence factor for Cryptococcus neoformans. Molecular Microbiology. 2001; 39
(1):166–75. PMID: 11123698
14. Djordjevic J, Del Poeta M., Sorrell TC., Turner KM., Wright LC. Secretion of cryptococcal phospholi-
pase B1 (PLB1) is regulated by a glycosylphosphatidylinositol (GPI) anchor. Biochem J. 2005; 389(Pt
3):803–14. doi: 10.1042/BJ20050063 PMID: 15826239
15. Siafakas AR, Wright LC, Sorrell TC, Djordjevic JT. Lipid Rafts in Cryptococcus neoformans Concen-
trate the Virulence Determinants Phospholipase B1 and Cu/Zn Superoxide Dismutase. Eukaryotic
Cell. 2006; 5(3):488–98. doi: 10.1128/EC.5.3.488-498.2006 PMID: 16524904
16. Waterman SR, Hacham M, Panepinto J, Hu G, Shin S, Williamson PR. Cell Wall Targeting of Laccase
of Cryptococcus neoformans during Infection of Mice. Infection and Immunity. 2007; 75(2):714–22.
doi: 10.1128/IAI.01351-06 PMID: 17101662
17. Zhu X, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR. Laccase of Cryptococcus neofor-
mans Is a Cell Wall-Associated Virulence Factor. Infection and Immunity. 2001; 69(9):5589–96. doi:
10.1128/IAI.69.9.5589-5596.2001 PMID: 11500433
18. Nile AH, Tripathi A, Yuan P, Mousley CJ, Suresh S, Wallace IM, et al. PITPs as targets for selectively
interfering with phosphoinositide signaling in cells. Nat Chem Biol. 2014; 10(1):76–84. http://www.
nature.com/nchembio/journal/v10/n1/abs/nchembio.1389.html#supplementary-information. doi: 10.
1038/nchembio.1389 PMID: 24292071
19. Agu´ndez JAG, Garcı´a-Martı´n E, Alonso-Navarro H, Jime´nez-Jime´nez FJ. Anti-Parkinson’s disease
drugs and pharmacogenetic considerations. Expert Opinion on Drug Metabolism & Toxicology. 2013;
9(7):859–74.
20. Lamos EM, Levitt DL, Munir KM. A review of dopamine agonist therapy in type 2 diabetes and effects
on cardio-metabolic parameters. Primary Care Diabetes. 2016; 10(1):60–5. doi: 10.1016/j.pcd.2015.
10.008 PMID: 26670921
21. Nyholm D. Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease. Clinical Pharmaco-
kinetics. 2013; 45(2):109–36.
22. Patniyot IR, Gelfand AA. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic
Review. Headache: The Journal of Head and Face Pain. 2016; 56(1):49–70.
23. Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness
and sleep disorders in Parkinson’s disease: Systematic review and meta-analysis. Parkinsonism &
Related Disorders. 2016.
24. Saper JR, Evans RW. Oral Methylergonovine Maleate for Refractory Migraine and Cluster Headache
Prevention. Headache: The Journal of Head and Face Pain. 2013; 53(2):378–81.
25. Werneke U, TURNER T, PRIEBE S. Complementary medicines in psychiatry. Review of effectiveness
and safety. 2006; 188(2):109–21.
26. Hoepfner D, Helliwell SB, Sadlish H, Schuierer S, Filipuzzi I, Brachat S, et al. High-resolution chemical
dissection of a model eukaryote reveals targets, pathways and gene functions. Microbiological
Research. 2014; 169(2–3):107–20. doi: 10.1016/j.micres.2013.11.004 PMID: 24360837
27. Richie DL, Thompson KV, Studer C, Prindle VC, Aust T, Riedl R, et al. Identification and Evaluation of
Novel Acetolactate Synthase Inhibitors as Antifungal Agents. Antimicrobial Agents and Chemother-
apy. 2013; 57(5):2272–80. doi: 10.1128/AAC.01809-12 PMID: 23478965
28. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jaramillo DF, et al. Chemogenomic profiling:
Identifying the functional interactions of small molecules in yeast. Proceedings of the National Acad-
emy of Sciences of the United States of America. 2004; 101(3):793–8. doi: 10.1073/pnas.0307490100
PMID: 14718668
29. Fang M, Kearns BG., Gedvilaite A., Kagiwada S., Kearns M., Fung MK., Bankaitis VA. Kes1p shares
homology with human oxysterol binding protein and participates in a novel regulatory pathway for
yeast Golgi-derived transport vesicle biogenesis. EMBO J. 1996; 15(23):6447–59. PMID: 8978672
30. Li X, Rivas MP, Fang M, Marchena J, Mehrotra B, Chaudhary A, et al. Analysis of oxysterol binding
protein homologue Kes1p function in regulation of Sec14p-dependent protein transport from the yeast
Golgi complex. The Journal of Cell Biology. 2002; 157(1):63–78. doi: 10.1083/jcb.200201037 PMID:
11916983
Antifungal Ergolines Target Sec14p
PLOS Genetics | DOI:10.1371/journal.pgen.1006374 November 17, 2016 17 / 19
31. Sreenivas A, Patton-Vogt JL, Bruno V, Griac P, Henry SA. A Role for Phospholipase D (Pld1p) in
Growth, Secretion, and Regulation of Membrane Lipid Synthesis in Yeast. Journal of Biological Chem-
istry. 1998; 273(27):16635–8. PMID: 9642212
32. Xie F, Rivas, Faulkner, Sternweis, Engebrecht, Bankaitis. Phospholipase D activity is required for sup-
pression of yeast phosphatidylinositol transfer protein defects. Proc Natl Acad Sci U S A 1998; 95
(21):12346–51. PMID: 9770489
33. Nikawa J, Tsukagoshi Y, Yamashita S. Isolation and characterization of two distinct myo-inositol trans-
porter genes of Saccharomyces cerevisiae. Journal of Biological Chemistry. 1991; 266(17):11184–91.
PMID: 2040626
34. Huang Z, Chen K, Zhang J, Li Y, Wang H, Cui D, et al. A Functional Variomics Tool for Discovering
Drug-Resistance Genes and Drug Targets. Cell Reports. 2013; 3(2):577–85. doi: 10.1016/j.celrep.
2013.01.019 PMID: 23416056
35. Bankaitis VA, Mousley CJ, Schaaf G. The Sec14 superfamily and mechanisms for crosstalk between
lipid metabolism and lipid signaling. Trends in Biochemical Sciences. 2010; 35(3):150–60. doi: 10.
1016/j.tibs.2009.10.008 PMID: 19926291
36. Schaaf G, Ortlund EA, Tyeryar KR, Mousley CJ, Ile KE, Garrett TA, et al. Functional Anatomy of Phos-
pholipid Binding and Regulation of Phosphoinositide Homeostasis by Proteins of the Sec14 Superfam-
ily. Molecular Cell. 2008; 29(2):191–206. doi: 10.1016/j.molcel.2007.11.026 PMID: 18243114
37. Khan D, McGrath KR, Dorosheva O, Bankaitis VA, Tripathi A. Structural elements that govern Sec14-
like PITP sensitivities to potent small molecule inhibitors. Journal of Lipid Research. 2016; 57(4):650–
62. doi: 10.1194/jlr.M066381 PMID: 26921357
38. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line
Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483
(7391):603–307. doi: 10.1038/nature11003 PMID: 22460905
39. Fang Y, Qin Y, Zhang N, Wang J, Wang H, Zheng X. DISIS: Prediction of Drug Response through an
Iterative Sure Independence Screening. PLoS ONE. 2015; 10(3):e0120408. doi: 10.1371/journal.
pone.0120408 PMID: 25794193
40. Miret S, De Groene EM, Klaffke W. Comparison of In Vitro Assays of Cellular Toxicity in the Human
Hepatic Cell Line HepG2. Journal of Biomolecular Screening. 2006; 11(2):184–93. doi: 10.1177/
1087057105283787 PMID: 16314402
41. Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, et al. Trends in Antifungal
Drug Susceptibility of Cryptococcus neoformans Isolates in the United States: 1992 to 1994 and 1996
to 1998. Antimicrobial Agents and Chemotherapy. 2001; 45(11):3065–9. doi: 10.1128/AAC.45.11.
3065-3069.2001 PMID: 11600357
42. Bicanic T MG, Rebe K, Williams A, Loyse A, Wood R, Hayes M, Jaffar S, Harrison T. Immune reconsti-
tution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir
Immune Defic Syndr. 2009; 51(2):5.
43. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity
and mechanisms of resistance. Expert Review of Anti-infective Therapy. 2009; 7(8):981–98. doi: 10.
1586/eri.09.67 PMID: 19803707
44. Sanglard D. Resistance of human fungal pathogens to antifungal drugs. Current Opinion in Microbiol-
ogy. 2002; 5(4):379–85. PMID: 12160856
45. Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, Romano L, et al. Identification and
characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding
gene, CnAFR1, involved in the resistance to fluconazole. Molecular Microbiology. 2003; 47(2):357–71.
PMID: 12519188
46. Vendetti N, Bryan M, Zaoutis TE, Damianos A, Fisher BT. Comparative effectiveness of fungicidal vs.
fungistatic therapies for the treatment of paediatric candidaemia. Mycoses. 2016; 59(3):173–8. doi: 10.
1111/myc.12449 PMID: 26692326
47. Liu T-B, Perlin DS, Xue C. Molecular mechanisms of cryptococcal meningitis. Virulence. 2012; 3
(2):173–81. doi: 10.4161/viru.18685 PMID: 22460646
48. Vu K, Tham R, Uhrig JP, Thompson GR, Na Pombejra S, Jamklang M, et al. Invasion of the Central
Nervous System by Cryptococcus neoformans Requires a Secreted Fungal Metalloprotease. mBio.
2014; 5(3):e01101–14. doi: 10.1128/mBio.01101-14 PMID: 24895304
49. Alspaugh JA. Virulence mechanisms and Cryptococcus neoformans pathogenesis. Fungal Genetics
and Biology. 2014;(78: ):55–8.
50. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astromoff A, et al. Genomic profiling of
drug sensitivities via induced haploinsufficiency. Nat Genet. 1999; 21(3):278–83. doi: 10.1038/6791
PMID: 10080179
Antifungal Ergolines Target Sec14p
PLOS Genetics | DOI:10.1371/journal.pgen.1006374 November 17, 2016 18 / 19
51. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, et al. Discovering Modes of Action
for Therapeutic Compounds Using a Genome-Wide Screen of Yeast Heterozygotes. Cell. 2004; 116
(1):121–37. PMID: 14718172
52. Roemer T, Xu D, Singh Sheo B, Parish Craig A, Harris G, Wang H, et al. Confronting the Challenges of
Natural Product-Based Antifungal Discovery. Chemistry & Biology. 2011; 18(2):148–64.
53. Li X, Routt SM, Xie Z, Cui X, Fang M, Kearns MA, et al. Identification of a Novel Family of Nonclassic
Yeast Phosphatidylinositol Transfer Proteins Whose Function Modulates Phospholipase D Activity
and Sec14p-independent Cell Growth. Molecular Biology of the Cell. 2000; 11(6):1989–2005. PMID:
10848624
54. Onge R, Schlecht U., Scharfe C., Evangelista M. Forward Chemical Genetics in Yeast for Discovery of
Chemical Probes Targeting Metabolism. Molecules. 2012; 17(11):13098–115. doi: 10.3390/
molecules171113098 PMID: 23128089
55. Sha B, Phillips SE, Bankaitis VA, Luo M. Crystal structure of the Saccharomyces cerevisiae phosphati-
dylinositol- transfer protein. Nature. 1998; 391(6666):506–10. doi: 10.1038/35179 PMID: 9461221
56. Bankaitis VA, Aitken JR, Cleves AE, Dowhan W. An essential role for a phospholipid transfer protein in
yeast Golgi function. Nature. 1990; 347(6293):561–2. doi: 10.1038/347561a0 PMID: 2215682
57. Phillips SE, Vincent P, Rizzieri KE, Schaaf G, Bankaitis VA, Gaucher EA. The Diverse Biological Func-
tions of Phosphatidylinositol Transfer Proteins in Eukaryotes. Critical Reviews in Biochemistry and
Molecular Biology. 2006; 41(1):21–49. doi: 10.1080/10409230500519573 PMID: 16455519
58. Lee AY, St.Onge RP, Proctor MJ, Wallace IM, Nile AH, Spagnuolo PA, et al. Mapping the Cellular
Response to Small Molecules Using Chemogenomic Fitness Signatures. Science (New York, NY).
2014; 344(6180):208–11.
59. De Grooth ANJA, van Dongen PWJ, Vree TB, Hekster YA, van Roosmalen J. Ergot Alkaloids–Current
Status and Review of Clinical and Therapeutic Use Compared with Other Oxytocics in Obstetrics and
Gynaecology. Drugs. 1998; 56:523–35. PMID: 9806101
60. Tanret C. Sur la presence d’un nouvel alkaloide, l’ergotinine, dans le seigle egote´. C R Acad Sci. 1875;
81:2.
61. Sinz A. Die Bedeutung der Mutterkorn-Alkaloide als Arzneistoffe. Pharm Unserer Zeit. 2008; 4:4.
62. Silberstein SD, McCrory DC. Ergotamine and Dihydroergotamine: History, Pharmacology, and Effi-
cacy. Headache: The Journal of Head and Face Pain. 2003; 43(2):144–66.
63. Pierce SE, Davis RW, Nislow C, Giaever G. Genome-wide analysis of barcoded Saccharomyces cere-
visiae gene-deletion mutants in pooled cultures. Nat Protocols. 2007; 2(11):2958–74. doi: 10.1038/
nprot.2007.427 PMID: 18007632
64. Gasteiger C. JR; Sadowski J. Automatic Generation of 3D Atomic Coordinates for Organic Molecules.
Tetrahedron Comp Method. 1990; 3:548.
65. Guagnano V, Kauffmann A, Wo¨hrle S, Stamm C, Ito M, Barys L, et al. FGFR Genetic Alterations Pre-
dict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor. Cancer Discovery. 2012; 2
(12):1118–33. doi: 10.1158/2159-8290.CD-12-0210 PMID: 23002168
66. Obach RS. Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic
Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Micro-
somes. Drug Metabolism and Disposition. 1999; 27(11):1350–9. PMID: 10534321
67. Wohnsland F, Faller B. High-Throughput Permeability pH Profile and High-Throughput Alkane/Water
log P with Artificial Membranes. Journal of Medicinal Chemistry. 2001; 44(6):923–30. PMID: 11300874
Antifungal Ergolines Target Sec14p
PLOS Genetics | DOI:10.1371/journal.pgen.1006374 November 17, 2016 19 / 19
